SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: John R. Sashko who wrote (1087)2/5/1999 12:04:00 PM
From: SkyDart  Read Replies (1) | Respond to of 2539
 
My doctor friends tell me that Celebrex is phenomenol.

Patients who are sensitive to all other anti-inflammatories CAN handle Celebrex.

And Celebrex seems to be more effective in pain relief than the others.

Huge market for NSAIDs [anti-inflammatories] with many brands like Relafen, Daypro, Motrin, Naprosyn, Voltaren, Arthrotec.

But Celebrex represents an order of magnitude improvement...and should capture much of this market.

Based upon the 55,000 first two week script data, this drug should do for MTC what Vaigra did for Pfizer.

Dart



To: John R. Sashko who wrote (1087)2/23/1999 4:02:00 PM
From: Anthony Wong  Read Replies (2) | Respond to of 2539
 
John, I recall that you'd earlier mentioned you had been invited to attend a lecture on Celebrex on Feb. 22. Did you attend? Your comments on the lecture/Celebex launch/any tidbits of info would be most appreciated.

Anthony


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News